Nicholas Company Inc. Purchases 4,655 Shares of IQVIA Holdings Inc. $IQV

Nicholas Company Inc. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 80,386 shares of the medical research company’s stock after buying an additional 4,655 shares during the quarter. Nicholas Company Inc.’s holdings in IQVIA were worth $18,120,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Swiss Life Asset Management Ltd increased its stake in shares of IQVIA by 8.1% during the fourth quarter. Swiss Life Asset Management Ltd now owns 36,819 shares of the medical research company’s stock worth $8,299,000 after purchasing an additional 2,749 shares during the period. Brummer Multi Strategy AB acquired a new stake in IQVIA during the fourth quarter worth approximately $1,845,000. Kepler Cheuvreux Suisse SA acquired a new stake in IQVIA during the fourth quarter worth approximately $1,229,000. Pure Financial Advisors LLC grew its position in IQVIA by 7.2% during the fourth quarter. Pure Financial Advisors LLC now owns 11,731 shares of the medical research company’s stock worth $2,644,000 after buying an additional 792 shares in the last quarter. Finally, Advisor OS LLC grew its position in IQVIA by 16.1% during the fourth quarter. Advisor OS LLC now owns 1,245 shares of the medical research company’s stock worth $281,000 after buying an additional 173 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.1%

Shares of NYSE:IQV opened at $178.48 on Monday. The firm has a market cap of $29.79 billion, a P/E ratio of 22.12, a P/E/G ratio of 1.72 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The business has a fifty day simple moving average of $170.14 and a 200 day simple moving average of $200.95.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IQV. JPMorgan Chase & Co. reduced their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Mizuho set a $215.00 price target on IQVIA in a research report on Monday, February 23rd. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research report on Friday, March 6th. BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Finally, Evercore reissued an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.